冠心病合并糖尿病患者血浆中凝血酶激活的纤溶抑制物变化  

The Changes of Thrombin Activatable Fibrinolysis Inhibitor in Coronary Atherosclerotic Heart Disease with Diabetes

作　　者：许延路[1] 王淑廷 朱媛媛[3] 李继福[3] 徐从高[3] 

机构地区：[1]山东省交通医院血栓病区,济南250031 [2]山东沂水黄山医院,临沂276420 [3]山东大学齐鲁医院,济南250012

出　　处：《血栓与止血学》2010年第3期113-114,共2页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的探讨冠心病(CAD)合并糖尿病患者血浆中凝血酶激活的纤溶抑制物变化。方法分别应用ELISA法、发色底物法测定40例冠状动脉造影(CAG)正常者和60例经CAG证实的CAD(伴糖尿病者17例)患者血浆中TAFI:Ag、TAFI:A含量。结果 CAD患者血浆中TAFI:Ag95±34%、TAFI:A29.2±11.2μg/ml,均显著高于CAG正常者(P<0.001);伴糖尿病患者TAFI:Ag113±28%、TAFI:A33.9±6.8μg/ml亦明显高于非糖尿病CAD(P<0.01)。结论 CAD患者血浆中TAFI:Ag和TAFI:A含量明显升高,伴糖尿病患者血浆中TAFI含量亦显著高于非糖尿病者,提示糖代谢异常使得冠心病患者纤溶功能进一步降低。Objective To discuss The changes of thrombin activatable fibrinolysis inhibitor in coronary atherosclerotic heart disease（CAD） patients with diabetes。 Methods There are 40 healthy adults as controls and 60 CAD patients（17 cases of patients with diabetes） in the study,all of the people were approved by coronary angiography （CAG）.The plasma levels of TAFI：Ag,TAFI：A were examined respectively with enzyme linked immunoadsordent assay（ELISA） or chrimato-substrate assay （CSA）.Results The mean of the plasma TAFI：Ag,TAFI：A for CAD patients is 95±34%,29.2±11.2 μg/ml,both of these variances are significant as compared with the controls（ P 0.001）,and the TAFI：A 113±28%,TAFI：A 33.9 ± 6.8 μg/ml of patients with diabetes was significantly higher than that of the CAD（ P 0.01）.Conclusion The level of TAFI：Ag and TAFI：A in patients with CAD is higher,and plasma TAFI contents in Diabetic patients is also significantly higher than that of non-diabetics,indicate that abnormal glucose metabolism further reduce the fibrinolytic function in patients with CAD.

关 键 词：冠心病 糖尿病 凝血酶激活的纤溶抑制物 

分 类 号：R541.4[医药卫生—心血管疾病]